FCN-338
FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor with an IC50 of 4.5 nM for Bcl-2/BAK interaction. FCN-338 potently inhibits tumor growth in follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenograft mice model without significant weight loss. FCN-338 has a broad-spectrum anti-cancer activity, such as FL, CLL/SLL, AML, and ALL[1][2].
Product Specifications
CAS Number
2248046-39-9
Product Name Alternative
LOXO-338
UNSPSC
12352005
Target
Bcl-2 Family
Related Pathways
Apoptosis
Field of Research
Cancer
Smiles
ClC1=CC=C(C=C1)C(CC(C)(CC2)C)=C2CN3CCN(C4=CC=C(C(NS(=O)(C5=CC(OC6)=C(C([N+]([O-])=O)=C5)N[C@H]6CC7=CC=CC=C7)=O)=O)C(OC8=CN=C9NC=CC9=C8)=C4)CC3
Molecular Formula
C48H48ClN7O7S
Molecular Weight
902.46
References & Citations
[1]Brandhuber B, et al. Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor[J]. Cancer Research, 2021, 81 (13_Supplement) : 1258-1258.|[2]Vogler M, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct Target Ther. 2025 Mar 21;10 (1) :91.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bcl-2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
